Pre‑conception Management of GLP‑1 Receptor Agonists and Tirzepatide

Timing of Discontinuation

• Semaglutide should be stopped at least 2 months before a planned conception to ensure drug clearance. 1
• The Endocrine Society and the European Society of Endocrinology (2025 joint guideline) conditionally recommend discontinuing all GLP‑1 receptor agonists before pregnancy (very low‑certainty evidence). 2, 3
• Tirzepatide follows the same pre‑conception discontinuation strategy as semaglutide—it must be stopped before attempting conception, not after pregnancy confirmation. 2, 1

Rationale & Fetal Risks

• Animal studies (rats, rabbits, cynomolgus monkeys) show embryofetal mortality, visceral and skeletal malformations, and growth alterations at exposures comparable to clinical doses, supporting the need for pre‑conception cessation. 2, 1
• GLP‑1 receptors are present in the human placenta; although placental transfer appears minimal, the effect on placental GLP‑1 signaling is unknown. 4, 5

Contraception and Fertility Considerations

• Women using semaglutide should maintain effective contraception throughout therapy rather than stopping contraception and the drug after pregnancy occurs. 4, 5
• GLP‑1 receptor agonists enhance fertility, increasing the risk of unplanned pregnancies; therefore, counseling on contraception is essential. 4, 5
• Approximately 40 % of pregnancies in the United States are unintended, and the fertility‑enhancing effect of GLP‑1RAs heightens this risk. 4, 5

Glycemic Management After Discontinuation

• Active glycemic control must be continued after stopping therapy to avoid hyperglycemia‑related teratogenicity during organogenesis. 2, 1
• Abrupt cessation can cause rebound hyperglycemia and weight gain, both of which raise the risk of congenital malformations and spontaneous abortion. 2, 1

Tirzepatide‑Specific Guidance

• Tirzepatide is a dual GLP‑1/GIP agonist with distinct structure, pharmacokinetics, and potency, requiring independent evaluation from other GLP‑1RAs. 2, 1
• The timing of tirzepatide discontinuation should be individualized based on the patient’s likelihood of conception after stopping contraception, the specific medication used, and the risks associated with prolonged therapy interruption. 2, 1

Management If Pregnancy Is Detected

• Immediately discontinue the GLP‑1RA or tirzepatide upon pregnancy confirmation if the drug has not already been stopped. 4, 5
• Initiate intensive glucose monitoring to promptly identify and correct any hyperglycemia that may emerge after drug withdrawal. 4, 5
• Transition promptly to pregnancy‑safe glucose‑lowering agents: insulin is the preferred therapy; metformin has limited safety data and should not be used as first‑line in this context. 6, 7, 8
• Coordinate care between endocrinology and obstetrics to ensure seamless glycemic management during the transition period. 4, 5

Post‑Discontinuation Therapy Choice

• Do not continue GLP‑1RAs or tirzepatide during pregnancy, even if glycemic control was previously excellent; fetal risk outweighs maternal benefit. 4, 2, 5

Postpartum Glycemic Management in Breastfeeding Women

• For breastfeeding mothers, metformin and glyburide have established safety profiles and can be used for postpartum glycemic control. 6, 7

Preconception Discontinuation of Tirzepatide

Guideline Recommendation

• The 2025 Endocrine Society / European Society of Endocrinology joint guideline conditionally recommends stopping all GLP‑1 receptor agonists, including tirzepatide (a dual GLP‑1/GIP agonist), before conception rather than after pregnancy begins. This recommendation is based on very low‑certainty evidence because human pregnancy outcome data are lacking. 9

Fetal‑Risk Evidence (Animal Data)

• Animal reproductive‑toxicity studies at clinically relevant exposures show that tirzepatide administered during organogenesis causes embryofetal mortality, visceral and skeletal malformations, reduced fetal weight, and delayed ossification; these adverse outcomes occurred together with marked maternal weight loss. The data are considered high‑quality animal evidence. 9
• The U.S. FDA has not approved tirzepatide for use during pregnancy owing to these reproductive‑toxicity findings. 9

Pharmacokinetic Rationale for a 2‑Month Washout

• Tirzepatide’s elimination half‑life is approximately 5 days; a 2‑month (≈8‑week) washout period ensures that the drug is fully cleared before the critical period of organogenesis (gestational weeks 3–8). 9
• Because tirzepatide is structurally and pharmacokinetically distinct from standard GLP‑1 receptor agonists, its safety profile must be evaluated independently. 9

Metabolic Consequences of Abrupt Discontinuation

• Abrupt cessation of tirzepatide can lead to rebound hyperglycemia and weight gain, both of which increase teratogenic risk in the pre‑conception and early‑pregnancy periods. 9
• First‑trimester hyperglycemia is strongly associated with a higher incidence of congenital malformations and spontaneous abortion. 9

Fertility‑Enhancing Effects

• Tirzepatide enhances fertility, particularly in women with polycystic ovary syndrome, thereby raising the risk of unplanned pregnancy if effective contraception is not used. 9

Evidence‑Quality Summary

• The recommendation to stop tirzepatide before conception is supported by:
  
  • High‑quality animal reproductive‑toxicity data demonstrating dose‑dependent fetal harm.
  • A conditional guideline recommendation from the Endocrine Society / European Society of Endocrinology (very low certainty).
  • FDA labeling that advises against pregnancy exposure.
  • Established clinical evidence that first‑trimester hyperglycemia causes congenital anomalies. All of these points are derived from the same cited source. 9

Management of GLP‑1 Receptor Agonists in Women of Reproductive Age

Discontinuation Recommendations

• Women who are pregnant or planning pregnancy should stop GLP‑1 receptor agonists and switch to insulin for glycemic control; this is a conditional recommendation of the Endocrine Society and the European Society of Endocrinology based on very low‑certainty human evidence but high‑quality animal reproductive‑toxicity data【10】.
• After confirming pregnancy, intensive glucose monitoring is advised to detect rebound hyperglycemia that commonly follows GLP‑1RA withdrawal【11】.

Contraception Guidance

• Effective contraception must be maintained throughout GLP‑1RA therapy to avoid inadvertent exposure during early gestation【10】.
• GLP‑1RAs increase fertility, especially in women with polycystic ovary syndrome, contributing to the high rate (~40 %) of unintended pregnancies in the United States【10】.

Glycemic Management and Preferred Pharmacologic Alternatives

• Insulin is the only first‑line agent recommended for diabetes management during pregnancy in the United States, as endorsed by the American Diabetes Association Standards of Care【12】.
• Metformin is not recommended as a first‑line therapy during the transition from GLP‑1RA or in pregnancy for women with type 2 diabetes because these patients often have pronounced insulin deficiency and resistance that metformin cannot adequately address【10】.
• Insulin has decades of safety data in pregnancy and has been shown to improve perinatal outcomes when used to treat gestational and pre‑existing diabetes【12】.

Safety Evidence from Animal Studies

• High‑quality animal studies (rats, rabbits, cynomolgus monkeys) at exposure levels comparable to clinical doses demonstrate embryofetal mortality, visceral and skeletal malformations, reduced fetal weight, and delayed ossification; these adverse outcomes are linked to marked maternal weight loss【10】.

Human Evidence and Guideline Strength

• The Endocrine Society/European Society of Endocrinology joint guideline issues a conditional recommendation to discontinue GLP‑1RAs before conception, reflecting very low‑certainty human data but strong animal toxicity evidence【13】.
• The American Diabetes Association 2024 Standards of Care state that insulin is the first‑line agent for diabetes in pregnancy, while metformin and other oral agents are not recommended as first‑line because of placental transfer and concerns about long‑term offspring metabolic health【12】.

Risks Associated with Alternative Oral Agents

• Metformin readily crosses the placenta, achieving umbilical‑cord concentrations equal to or exceeding maternal levels; long‑term follow‑up of exposed offspring shows higher body‑mass index and increased waist circumference at ages 5–10 years【12】【13】.
• Sulfonylureas cross the placenta (cord plasma 50–70 % of maternal levels) and are associated with an increased risk of neonatal hypoglycemia【12】.
• The presence of GLP‑1 receptors in the human placenta and the unknown functional effects mean that minimal placental transfer cannot be assumed to indicate safety【10】.